Budget Impact and Incremental Survival Benefit of Using Lenvatinib as a Treatment for Radioactive Iodine Refractory Differentiated Thyroid Cancer in Russia
Abstract
Authors
U Majethia M Frolov S Podvyaznikov P Rumyantsev E Bukharova G Tremblay C Pelletier A Forsythe